Want to see KR:101140 full AI Analyst Report?
Top Page
INBIOGEN CO., Ltd.
(101140)
Select Model
Select Model
Rating:44Neutral
Price Target:
₩4,554.00
Action:N/A
Date:10/28/26
The score is primarily held back by weak financial performance—especially negative and persistent operating/free cash flow, negative gross profit in TTM, and unstable earnings—despite a conservatively levered balance sheet. Technicals add further pressure with a clear downtrend (price below key moving averages and negative MACD). Valuation provides limited support because the negative P/E reflects losses and dividend yield is unavailable.
Positive Factors
Conservative Leverage
Very low leverage reduces the company’s dependence on creditors and limits interest-related pressure on future cash flows. This provides financial flexibility to continue pharmaceutical development and commercial activities, while making the balance sheet better able to absorb operating volatility.
Negative Factors
Persistent Cash Burn
Consistently negative operating and free cash flow indicate that the core business is not currently funding itself through cash generation. Persistent outflows can constrain investment capacity, increase reliance on financing or asset resources, and weaken the durability of the business model.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative Leverage
Very low leverage reduces the company’s dependence on creditors and limits interest-related pressure on future cash flows. This provides financial flexibility to continue pharmaceutical development and commercial activities, while making the balance sheet better able to absorb operating volatility.
Read all positive factors
INBIOGEN CO., Ltd. (101140) vs. SPDR S&P 500 ETF (SPY)
Market Cap
₩47.68B
Dividend YieldN/A
Average Volume (3M)3.58K
Price to Earnings (P/E)―
Beta (1Y)0.20
Revenue Growth-34.04%
EPS Growth-139.58%
CountryKR
Employees41
SectorGeneral
Sector StrengthN/A
IndustryApparel - Footwear & Accessories
Share Statistics
EPS (TTM)-4161.70
Shares Outstanding10,044,217
10 Day Avg. Volume1,212
30 Day Avg. Volume3,578
Financial Highlights & Ratios
PEG Ratio-0.28
Price to Book (P/B)0.67
Price to Sales (P/S)16.73
P/FCF Ratio-18.83
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
INBIOGEN CO., Ltd. Business Overview & Revenue Model
Company Description
Headquartered in Pyeongtaek, South Korea, INBIOGEN Co., Ltd. is a footwear manufacturer and distributor founded in 1949. The company produces and sells shoes for children, youth, and adults, serving both the South Korean domestic market and intern...
INBIOGEN CO., Ltd. Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
76
Positive
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.10B | 6.30B | 7.04B | 6.24B | 11.40B | 10.48B |
| Gross Profit | -546.60M | -574.39M | 660.07M | 1.28B | 2.56B | 1.96B |
| EBITDA | 5.47B | -3.97B | 17.23B | 13.34B | 45.46B | 116.01B |
| Net Income | -20.73B | 5.82B | 16.12B | 18.86B | -119.69B | 94.12B |
Balance Sheet | ||||||
| Total Assets | 146.88B | 159.99B | 162.73B | 151.31B | 141.81B | 274.47B |
| Cash, Cash Equivalents and Short-Term Investments | 2.34B | 901.70M | 5.72B | 6.09B | 9.29B | 23.15B |
| Total Debt | 4.05B | 1.17B | 894.79M | 593.26M | 1.77B | 13.41B |
| Total Liabilities | 5.38B | 2.35B | 2.89B | 2.62B | 37.40B | 96.45B |
| Stockholders Equity | 141.50B | 157.64B | 159.84B | 148.68B | 104.42B | 178.02B |
Cash Flow | ||||||
| Free Cash Flow | -3.64B | -5.60B | -117.41M | -1.38B | -11.84B | -9.47B |
| Operating Cash Flow | -3.64B | -5.55B | -33.13M | -1.05B | -11.51B | -7.07B |
| Investing Cash Flow | -29.37M | 466.48M | -74.22M | -192.72M | -15.92B | -40.44B |
| Financing Cash Flow | 3.27B | 272.97M | -265.30M | -1.96B | 13.57B | 61.54B |
INBIOGEN CO., Ltd. Technical Analysis
Negative
―
Price Trends
5090.80
Negative
5472.20
Negative
7525.20
Negative
Market Momentum
-66.29
Positive
42.50
Neutral
44.52
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KR:101140, the sentiment is Negative. The current price of undefined is equal to the 20-day moving average (MA) of 4865.25, equal to the 50-day MA of 5090.80, and equal to the 200-day MA of 7525.20, indicating a bearish trend. The MACD of -66.29 indicates Positive momentum. The RSI at 42.50 is Neutral, neither overbought nor oversold. The STOCH value of 44.52 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for KR:101140.
INBIOGEN CO., Ltd. Peers Comparison
UnderperformOutperform
Sector (55)
KR:101140
INBIOGEN CO., Ltd.
4,775.00
-8,255.00
-63.35%
KR:046210
HLB PANAGENE Co. LTD.
1,300.00
-407.00
-23.84%
KR:084650
LabGenomics Co., Ltd.
2,015.00
-9,910.00
-83.10%
KR:187420
HLB Genex, Inc.
2,300.00
-795.00
-25.69%
KR:314140
RPbio Inc.
5,300.00
-2,119.11
-28.56%
KR:950200
Psomagen Inc Shs Korean Depositary Receipt Repr 1 Sh
2,965.00
-635.00
-17.64%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.